Kura Oncology stock has November 3 results date
Published on 10/17/2026 at 22:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSScheduled results and valuation
- Kura Oncology is scheduled to report results on November 3, 2026.
- Second-quarter revenue reached USD 20.87 million versus USD 20.16 million expected on August 12, 2026.
- Kura Oncology stock was USD 9.08 at Nasdaq on October 16, 2026, down 6.39 percent versus the October 15, 2026 close.
- Kura Oncology had a market capitalization of USD 807.8 million on October 16, 2026.
Kura Oncology is scheduled to report its September 2026 results on November 3, 2026, according to MetaCap. The date gives investors the next fixed checkpoint for a company that is moving from clinical development toward commercial execution. Kura Oncology stock was last at USD 9.08 on October 16, 2026 at 4:00 p.m. EDT, down 6.39 percent on Nasdaq versus the prior close of October 15, 2026.
Revenue provides the next benchmark
Kura reported USD 20.87 million in second-quarter revenue on August 12, 2026, compared with USD 20.16 million expected, a 3.52 percent beat. The figures were reported by The Stock Observer, which also stated that adjusted loss per share was USD 0.77 against a USD 0.88 consensus loss. Kura's latest quarterly financials showed a net loss of USD 68.33 million and operating cash flow of minus USD 62.55 million in the second quarter of 2026.
Stock position after the decline
The October 16 close stood 34.68 percent below the 52-week high of USD 13.90 and 23.37 percent above the 52-week low of USD 7.36. Year to date, the stock was down 12.60 percent. Trading volume reached 1,780,627 shares against an average of 1,822,653 shares.
Valuation and upcoming dates
Kura's market capitalization was USD 807.8 million on October 16, 2026. The trailing P/E ratio was not meaningful because the company reported a net loss, while the dividend yield was 0.00 percent. Kura Oncology develops precision medicines for cancer, including the commercial product KOMZIFTI, according to Kura Oncology. The company listed an October 13, 2026 development update with Caspian Therapeutics on its investor calendar.
Comparison with peers
KURA (Nasdaq, USD): minus 6.39 percent, P/E minus 2.69, market capitalization USD 807.8 million.
Syndax Pharmaceuticals (Nasdaq, USD): minus 5.49 percent, P/E minus 5.12, market capitalization USD 1.2 billion.
Rigel Pharmaceuticals (Nasdaq, USD): minus 2.71 percent, P/E 2.82, market capitalization USD 858.7 million.
Price remains below the yearly high
The share price ended the October 16 Nasdaq session at USD 9.08, with the daily range between USD 9.05 and USD 9.68. The next scheduled reporting date is November 3, 2026.
Market context: Market report Nasdaq Composite.
